Mark Lewis, MD

Panelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.

Panelists discuss how the 24-month data from the GALAXY study presented at the European Society for Medical Oncology (ESMO) 2024 meeting underscore the importance of minimal residual disease (MRD) status and circulating tumor DNA (ctDNA) clearance as key prognostic and predictive factors in colorectal cancer (CRC) management.

Panelists discuss how treatment strategies for circulating tumor DNA (ctDNA)–positive colorectal cancer (CRC) are evolving, with a focus on tailoring interventions based on molecular findings to improve patient outcomes and minimize unnecessary therapies.

Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.

Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.

Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.

Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.

Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.

Panelists discuss how minimal residual disease (MRD) detection in colorectal cancer (CRC) is improving postsurgical treatment decision-making and enabling more effective monitoring of patient outcomes.

Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.

Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.

Drs. Cohen and Lewis close by outlining ongoing clinical trials in CRC and hopes for the future of care.

Stacy A. Cohen, MD and Mark Lewis, MD share key takeaways from the GALAXY study and discuss the clinical implications of using ctDNA-based assays for patients with CRC.

Experts describe cumulative ctDNA clearance rates in patients with stage I-IV disease who did or did not receive adjuvant chemotherapy in the GALAXY study.

Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.

GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.

Mark Lewis, MD, provides a historical perspective of circulating tumor DNA and discusses previous trials on ctDNA analysis in patients with CRC.

Stacy A. Cohen, MD, and Mark Lewis, MD, comment on disease-free survival rates by ctDNA status in patients enrolled in the GALAXY study.

Drs Cohen and Lewis review the GALAXY enrollment strategy and describe the various colorectal cancer patient cohorts in the study.

Stacey A. Cohen, MD, and Mark Lewis, MD, introduce the 2022 ASCO GI abstract, “Association of Circulating Tumor DNA Dynamics With Clinical Outcomes in the Adjuvant Setting for Patients With Colorectal Cancer From an Observational GALAXY Study in CIRCULATE-Japan.”